Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years

S. Filip, O. Kubeček, J. Špaček, M. Lánská, M. Bláha,

. 2020 ; 12 (10) : . [pub] 20200930

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21002038

Grant support
16-30366A Ministerstvo Zdravotnictví Ceské Republiky - International
PROGRES Q40/06 Univerzita Karlova v Praze - International

Cancer treatment has been greatly improved by the combined use of targeted therapies and novel biotechnological methods. Regarding the former, pegylated liposomal doxorubicin (PLD) has a preferential accumulation within cancer tumors, thus having lower toxicity on healthy cells. PLD has been implemented in the targeted treatment of sarcoma, ovarian, breast, and lung cancer. In comparison with conventional doxorubicin, PLD has lower cardiotoxicity and hematotoxicity; however, PLD can induce mucositis and palmo-plantar erythrodysesthesia (PPE, hand-foot syndrome), which limits its use. Therapeutical apheresis is a clinically proven solution against early PLD toxicity without hindering the efficacy of the treatment. The present review summarizes the pharmacokinetics and pharmacodynamics of PLD and the beneficial effects of extracorporeal apheresis on the incidence of PPE during chemoradiotherapy in cancer patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21002038
003      
CZ-PrNML
005      
20210126092707.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics12100940 $2 doi
035    __
$a (PubMed)33008072
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Filip, Stanislav $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, Charles University Prague, 50003 Hradec Králové, Czech Republic.
245    10
$a Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years. / $c S. Filip, O. Kubeček, J. Špaček, M. Lánská, M. Bláha,
520    9_
$a Cancer treatment has been greatly improved by the combined use of targeted therapies and novel biotechnological methods. Regarding the former, pegylated liposomal doxorubicin (PLD) has a preferential accumulation within cancer tumors, thus having lower toxicity on healthy cells. PLD has been implemented in the targeted treatment of sarcoma, ovarian, breast, and lung cancer. In comparison with conventional doxorubicin, PLD has lower cardiotoxicity and hematotoxicity; however, PLD can induce mucositis and palmo-plantar erythrodysesthesia (PPE, hand-foot syndrome), which limits its use. Therapeutical apheresis is a clinically proven solution against early PLD toxicity without hindering the efficacy of the treatment. The present review summarizes the pharmacokinetics and pharmacodynamics of PLD and the beneficial effects of extracorporeal apheresis on the incidence of PPE during chemoradiotherapy in cancer patients.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kubeček, Ondřej $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, Charles University Prague, 50003 Hradec Králové, Czech Republic.
700    1_
$a Špaček, Jiří $u Department of Gynecology and Obstetrics, Faculty of Medicine in Hradec Králové, Charles University Prague, 50003 Hradec Králové, Czech Republic.
700    1_
$a Lánská, Miriam $u 4th Department of Internal Medicine-Haematology, Faculty Hospital in Hradec Králové, 50005 Hradec Králové, Czech Republic.
700    1_
$a Bláha, Milan $u 4th Department of Internal Medicine-Haematology, Faculty Hospital in Hradec Králové, 50005 Hradec Králové, Czech Republic.
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 12, č. 10 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33008072 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092703 $b ABA008
999    __
$a ind $b bmc $g 1614121 $s 1122322
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 10 $e 20200930 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a 16-30366A $p Ministerstvo Zdravotnictví Ceské Republiky $2 International
GRA    __
$a PROGRES Q40/06 $p Univerzita Karlova v Praze $2 International
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options